Most stress signals induce apoptosis via a mitochondriadependent process, in which release of cytochrome c and other apoptogenic factors from mitochondria leads to the formation of apoptosome and activation of executioner caspases. 1, 2 As major regulators and effectors of this apoptotic pathway, the Bcl-2 family proteins control the immediate steps leading to the mitochondrial dysfunction. 3, 4 Members of this family, sharing one or several Bcl-2 homology (BH) domains, can be classified into the anti-apoptotic group, for example, Bcl-2, Bcl-xL, and Mcl-1, which protect the integrity of the mitochondria, and the pro-apoptotic members, which can be further divided into the multi-BH domain members, for example, Bax and Bak, and the BH3-only proteins, for example, Bad, Bid, Bim, Noxa, and Puma. In response to diverse apoptotic stimuli, activated BH3-only proteins directly or indirectly activate the multidomain proteins Bax and Bak, which in turn homo-oligomerize and permeabilize the mitochondrial outer membrane. [5] [6] [7] [8] [9] [10] It is believed that the anti-apoptotic family proteins inhibit Bax/Bak activation and mitochondrial dysfunction by sequestering either the BH3-only proteins or the Bax/Bak proteins. 7, 11, 12 Although it has been widely accepted that different apoptotic signals activate distinct BH3-only proteins, which in turn trigger the activation of the Bax/Bak proteins, in few instances, in which the triggering BH3-only protein has been unequivocally identified. 13 For example, Bid and Bim have been identified as the triggering proteins for mitochondrial dysfunction in cell surface death receptor-mediated pathway and in endoplasmic reticulum (ER) stress-induced pathway, respectively. [14] [15] [16] However, the triggering protein for mitochondrial dysfunction induced by most other apoptotic stimuli remains less clear. In addition, even in the well-characterized pathways, in which a triggering protein has been identified, it remains unclear whether other BH3-only proteins are also involved. Furthermore, for most apoptotic pathways, the exact targets of the involved BH3-only proteins have not been fully defined.
We used a combination of siRNA knockdown and biochemical assays to screen the entire collections of BH3-only and anti-apoptotic Bcl-2 proteins for their involvement in apoptosis induced by the three apoptotic stimuli mentioned above. Surprisingly, the BH3-only protein Noxa was found to be critically involved in all three pathways. Noxa is a BH3-only protein identified as a transcriptional target for p53. 17 Other studies found that Noxa can also be upregulated by DNA damage, ER stress, and proteasomal inhibition in a p53-independent manner, [18] [19] [20] [21] and that overexpression of Noxa was sufficient to induce apoptosis in HeLa cells and other cell types. 17, 22 Recent interaction studies have demonstrated that Noxa preferentially binds to Mcl-1, or A1, but not to Bcl-xL and Bcl-2. 23 On binding to Mcl-1, Noxa was found to neutralize its anti-apoptotic activity, and promote the degradation of Mcl-1. 24 However, as inactivation of Mcl-1 is not sufficient to induce apoptosis, 25 the mechanism of how upregulated Noxa induces apoptosis remains unclear. We recently identified a DNA damage-induced interaction between Noxa and Bcl-xL. 26 In this study, we defined the Bcl-2 network and the differential involvement of Noxa in three other apoptotic pathways.
Results
Screening for critical suppressors to apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL), ER Stress, and MG-132 among the Bcl-2-like proteins. To identify the rate-limiting steps in apoptosis pathways induced by TRAIL, ER stress, and proteasomal inhibition in HeLa cells, we first screened the anti-apoptotic Bcl-2 family proteins for critical suppressors of apoptosis. SiRNA duplexes were used to knockdown each of these proteins individually ( Figure 1a ). Of note, we could not detect the protein and mRNA of A1 in HeLa cells. Following siRNA transfection, the cells were treated with TRAIL, thapsigargin (TG, ER stress), or MG-132 (proteasome inhibitor; Figure 1b -d), and monitored for apoptosis. The knockdown of either Bcl-xL or Mcl-1, but not Bcl-2, greatly sensitized the cells to TRAIL, suggesting that both Bcl-xL and Mcl-1 are major inhibitors of TRAIL-induced apoptosis. The elimination of Bcl-xL, but not any other members, greatly sensitized cells to TG treatment, suggesting that Bcl-xL is a major inhibitor of TG-induced apoptosis (Figure 1c) . The knockdown of Mcl-1, or to a lesser extent, Bcl-xL, but not others, sensitized cells to MG-132 treatment, suggesting that Bcl-xL and Mcl-1, especially Mcl-1, are major rate-limiting proteins in this pathway (Figure 1d) .
We next investigated the combined role of Bcl-xL and Mcl-1 in the survival of HeLa cells. As shown in Figure 1e , the simultaneous knockdown of these two proteins resulted in potent apoptosis without any apoptotic stimulus, indicating that Bcl-xL and Mcl-1 together constitute a major survival mechanism in HeLa cells. These results also suggest that inactivation of both Bcl-xL and Mcl-1 may be a common rate-limiting step during apoptosis induced by multiple apoptosis pathways. Identification of Bid and Noxa as critical BH3-only proteins involved in TRAIL-induced apoptosis. Next, we examined the involvement of the BH3-only proteins in TRAIL-induced apoptosis by a similar siRNA screening. The knockdown of the target proteins was verified either by western blot analysis or by RT-PCR ( Figure 2a ). As expected, although knockdown of most of BH3-only proteins individually had little effect, the knockdown of Bid essentially abolished TRAIL-induced apoptosis (Figure 2b ). Unexpectedly, the knockdown of Noxa also conferred strong inhibition of Bak activation and apoptosis (Figure 2b and Supplementary Figure S1 ). Of note, we also verified the involvement of Noxa in TRAIL-induced apoptosis in H460 cells (Supplementary Figure S2 ).
To investigate the mechanism of involvement of Bid and Noxa in TRAIL-induced apoptosis, we examined the changes of these proteins following TRAIL treatment by western blot (Figure 2c ). Although no changes were observed for Bad, Bim, Noxa, Mcl-1, and Bcl-xL, Bid was cleaved into tBid after 3 h of TRAIL treatment. As both Bcl-xL and Mcl-1 are critically involved in suppressing apoptosis induced by TRAIL, we examined the potential interaction between the involved BH3-only proteins with Bcl-xL and Mcl-1 after TRAIL treatment. Two stable cell lines were generated that overexpress a polyhistidine-tagged Bcl-xL (Supplementary Figure S3) and a similarly tagged Mcl-1, respectively. Following TRAIL treatment, the cell extracts were passed through nickel affinity column to examine for the endogenous BH3-only proteins associated with either Bcl-xL or Mcl-1. Although Bad and Bim bound to Bcl-xL constitutively, tBid was generated and bound to Bcl-xL after 3 h (Figure 2d ). In contrast, no Noxa was found associated with His 9 -Bcl-xL before or after TRAIL treatment. Using 14,27
Next, we examined the binding of the relevant BH3-only proteins to either His 9 -Bcl-xL or His 9 -Mcl-1 following TG treatment. As expected, a gradual increase of Bim bound to Bcl-xL was observed. Surprisingly, a Noxa/Bcl-xL interaction was detected after 6 h (Figure 3c ). This TG-induced Noxa/ Bcl-xL interaction was also confirmed in cell extracts generated in CHAPS (Supplementary Figure S7) . In His 9 -Mcl-1cells, while Bim increased its binding to Mcl-1 following TG treatment, Noxa constitutively bound to Mcl-1 (Figure 3d ). These results suggest that while Bim serves as the major triggering proteins for mitochondrial dysfunction, Noxa may also be actively involved by binding to and inactivating endogenous Bcl-xL and Mcl-1 in this pathway.
Noxa as a major BH3-only protein involved in proteasome inhibition-induced apoptosis. SiRNA screening was used to examine the involvement of the BH3-only proteins in proteasomal inhibition-induced apoptosis. The knockdown of Noxa, but not any of the other nine known BH3-only proteins, potently inhibited MG-132-induced apoptosis, suggesting that Noxa is a major BH3-only protein required for MG-132-induced Bak activation and apoptosis (Figure 4a and Supplementary Figure S8 ). As expected, while Bid, Bad, Bim, and Bcl-xL remained unchanged, we observed a strong increase of both Noxa and Mcl-1 after MG-132 treatment. This increase is consistent with a transcriptional upregulation of Noxa and a blockade of degradation of Mcl-1 due to proteasomal inhibition. 25 We next examined the potential interaction between the BH3-only proteins and Bcl-xL or Mcl-1 using His 9 -Bcl-xL or His 9 -Mcl-1 cells. Surprisingly, while Bad and Bim bound Bcl-xL constitutively, Noxa became associated with Bcl-xL following MG-132 treatment. This MG-132-induced Noxa/ Bcl-xL interaction was also confirmed in cell extracts generated in CHAPS (Supplementary Figure S9) . In the pulldown analysis with His 9 -Mcl-1, while Bad did not show any binding, Bim constitutively bound Mcl-1. A steady increase of binding of Noxa to Mcl-1 was observed, presumably due to a concomitant increase of both His 9 -Mcl-1 and Noxa. These results suggest that Noxa is primarily responsible for MG-132-induced Bax/Bak activation and apoptosis by inactivating both Mcl-1 and Bcl-xL.
Generation of 'Mcl-1 free' Noxa and its binding to Bcl-xL at the endogenous level following TG or MG-132, but not TRAIL treatment. The apparent involvement of Noxa in all three apoptotic pathways examined prompted us to investigate the status of endogenous Noxa during apoptosis induced by these treatments. As shown in Figures 2, 3 , and 4, before any treatment, Noxa is associated with Mcl-1. We, therefore, examined the availability of 'Mcl-1 free' Noxa following these treatments. In our recent study, we developed an assay to detect the potential excess amount of Noxa free from endogenous Mcl-1. 26 In this assay, at different time points following treatment by different stimuli, HeLa cells extracts were generated and incubated with GST-Mcl-1 or GST at 41C to detect any free Noxa that is not associated with the endogenous Mcl-1. GST-Mcl-1 was unable to pulldown any Noxa from lysates from untreated or compared with that between Bcl-xL and Noxa, we would expect that GST-Mcl-1 may compete Noxa away from Bcl-xL even from the Bcl-xL/Noxa complex in the in vitro association assay carried out at 41C. 26 The status of Noxa after apoptotic stimulation was also examined by immunoprecipitation by an antibody against Mcl-1. As shown in Figure 5b , in extracts depleted of Mcl-1, we were able to detect Noxa after TG and MG-132 treatments, but not after TRAIL treatment. These results show the generation of 'Mcl-1 free' Noxa during TG-and MG-132-, but not TRAIL-induced apoptosis.
Next, we tested whether the induced Noxa/Bcl-xL interaction after TG or MG-132 can occur at the endogenous level. HeLa cells were treated with TRAIL, TG, or MG-132, and harvested at different time points after each treatment. The cell extracts were subjected to immunoprecipitation by either a control IgG or an antibody against Bcl-xL. As shown in Figure 6 , Noxa was found associated with Bcl-xL following treatment by TG or MG-132, but not by TRAIL, suggesting that Noxa may be able to neutralize endogenous Bcl-xL in an inducible manner. (Figure 7a ). After induction, cell extracts were generated and subjected to immunoprecipitation by either the control IgG or the Bcl-xL antibody. As expected, the Bcl-xL antibody was able to pulldown the wild-type Noxa, but not the BH3 mutant, suggesting the BH3 dependence of this interaction (Figure 7b) . Furthermore, as shown in Figure 7c , the induced expression of Noxa, but not its BH3 mutant or GFP caused significant apoptosis in HeLa cells. To further determine the specificity of apoptosis induced by Noxa upregulation, we established HeLa cells that inducibly express mouse Bad (Figure 7d) . In contrast to Noxa induction, the inducible expression of Bad failed to induce apoptosis in HeLa cells. However, the induction of Bad greatly sensitized the cells to TRAIL, TG, or MG-132 treatment (Figure 7e-g) . As inactivation or neutralization of both Bcl-xL and Mcl-1 is necessary for apoptosis (Figure 1e) , these results support the notion that, while Bad targets mostly Bcl-xL, Noxa is able to target both Mcl-1 and Bcl-xL in vivo.
Apoptosis in HeLa cells

Discussion
In this study, we used a loss-of-function approach to systematically screen the Bcl-2 family proteins for their critical involvement in mitochondria-dependent apoptosis in HeLa cells. Combined with interaction and functional studies, this approach enabled us to define the unique Bcl-2 networks necessary for apoptosis induced by DNA damage in our recent study 26 and by three other major apoptosis stimuli in this study. Importantly, our results suggest the involvement of selective Bcl-2 networks and differential mechanisms of how BH3-only protein Noxa in triggering mitochondrial dysfunction in response to different apoptotic stimuli (Figure 8 ).
Distinct Bcl-2 network in a given cell is responsible for apoptosis induced by different stimuli. By screening the anti-apoptotic Bcl-2 members, we found Bcl-xL and Mcl-1 are two major components of the cell survival machinery in these cells. This result is consistent with a synergy in apoptosis induction between Bad and Noxa, which preferentially target Bcl-xL and Mcl-1, respectively. 23 Similarly, ABT-737, a BH3 peptidomimetic compound that most closely resembled Bad BH3, showed strong synergistic killing together with a loss of Mcl-1, 28, 29 suggesting that apoptosis signaling pathways converge on the functional inactivation of both Bcl-xL and Mcl-1. The lack of effect of Bcl-2 knockdown on apoptosis (Figure 1 ) is consistent with an earlier finding in HeLa and mouse embryonic fibroblasts (MEFs). 24 It is possible that the endogenous Bcl-2 is differentially inhibited in HeLa cells or MEFs, although overexpression of Bcl-2 was able to suppress apoptosis in HeLa cells (Supplementary Figure S3) .
It has been well accepted that the mitochondrial pathway is initiated during cell surface death receptor-mediated apoptosis after the generation of tBid by caspase-8. 15, 16 The involvement of Noxa suggests that at least in some cells, generation of tBid alone is not sufficient to initiate the mitochondrial pathway. Similarly, it is somewhat surprising that knockdown of Noxa impeded ER stress-induced apoptosis, indicating that although Bim is a potent apoptosis inducer, it is not sufficient for apoptosis in certain cells. These Cells lysates were then subjected to immunoprecipitation using Bcl-xL antibody or IgG control antibody as described in the Material and Methods. The lysates and immunoprecipitates were loaded onto SDS-PAGE. Western blots were probed by anti-Noxa and anti-Bcl-xL antibodies results highlight the critical role of in vivo cooperativity among the BH3-only proteins during apoptosis.
Noxa constitutively suppresses Mcl-1 function before apoptotic signaling. The role of Noxa in TRAIL pathway is unexpected because Noxa is normally considered an inducible BH3-only protein that functions only when it is upregulated. 21 It seems that Noxa is involved in TRAILinduced apoptosis through Mcl-1, a potent inhibitor of this pathway. As Noxa was found to be associated with Mcl-1 constitutively, it is reasonable to suggest that Noxa functions as a constitutive inhibitor for Mcl-1, which is known to sequester both tBid and Bak. 30, 31 The elimination of Noxa would, therefore, effectively cause an increase of free/active Mcl-1, which in turn inhibits mitochondrial damage and apoptosis at least in part by sequestering more active Bak (Supplementary Figures S4 and S5) . Consistent with this notion, knockdown of Mcl-1 by siRNA greatly sensitized HeLa cells to TRAIL (Figure 1 ). It is interesting that among the 10 BH3-only proteins, only Noxa was identified as a helper for tBid. It can be speculated that other BH3-only proteins, for example Bad, BimEL, or Puma, are not involved because of the to differential compartmentalization, lower in vivo affinity for Mcl-1, lower in vivo concentrations, or differential post-translational modification in this setting.
Noxa as an induced inactivator of Bcl-xL in ER stressand proteasomal inhibition induced-apoptosis. As our results do not exclude the possibility that multiple BH3-only proteins, in addition to Noxa and Bim, are involved in neutralizing Bcl-xL, we also screened for BH3-only proteins that inducibly interact with the Bcl-xL following TG or MG-132 treatment (Supplementary Figure S10A) . Interestingly, Bmf and Puma showed increased binding to His 9 -Bcl-xL after TG treatment. Therefore, we carried out the double knockdown of Bmf and Puma, and tested its effect on TG-induced apoptosis in HeLa cells (Supplementary Figures S10B and C) . Similar to the single knockdowns, the double knockdown did not have any effect on apoptosis, making a simultaneous involvement of these two proteins in TG-induced apoptosis unlikely. Similarly, Bik and tBid also showed an increase in binding to His 9 -Bcl-xL following MG-132 treatment (Supplementary Figure S11A) . However, the double knockdown of Bik and Bid failed to block apoptosis (Supplementary Figures S11B and C), suggesting that the combined actions of these two proteins are not necessary for MG-132-induced apoptosis.
What is the consequence of the induced interaction between Noxa and Bcl-xL? Although mouse Noxa has originally been reported to interact with Bcl-xL when both Noxa and Bcl-xL are overexpressed, 17 it has been subsequently demonstrated that human Noxa interacted with only Mcl-1, but not Bcl-2 or Bcl-xL. 23, 24 However, this stringent selectivity is not fully consistent with the observation that overexpression of Noxa was sufficient to induce apoptosis ( Figure 7 ). As shown in Figure 1 , only the simultaneous elimination of both Bcl-xL and Mcl-1 was sufficient to induce apoptosis, suggesting that the triggering protein(s) need to inactivate both Bcl-xL and Mcl-1 to effect mitochondrial damage in HeLa cells. Although the induced Noxa/Bcl-xL interaction seemed weak in the in vitro experiments (Figures 3, 4, 6 , and 7), the apoptosis induced by Noxa upregulation (Figure 7 ) strongly suggests that this interaction happens in vivo, and that Noxa is able to neutralize both Mcl-1 and Bcl-xL.
How does Noxa induce mitochondrial dysfunction and Bax/Bak activation? Inactivation of both Mcl-1 and Bcl-xL may trigger mitochondrial dysfunction through either direct or indirect pathways leading to the activation of Bax/Bak. [5] [6] [7] 27 According to the direct activation model, once Mcl-1 and BclxL are neutralized, the direct activator BH3-only proteins, for example, tBid, Bim, or PUMA, may be released and they in turn directly activate Bax or Bak. 8 Although the knockdown of these three factors individually had no effects in the MG-132-induced pathway (Figure 4) , it remains possible that all three of these proteins were simultaneously released from Mcl-1 and Bcl-xL, and either one of them may directly activate Bax/ Bak. On the other hand, the indirect model would suggest that the inactivation of Mcl-1 and Bcl-xL by Noxa may cause these two proteins to release Bax or Bak, allowing homooligomerization and activation of Bax/Bak, which would subsequently damage the mitochondria. 11, 24 FRET analysis on the outer membrane of the mitochondria may be used in future studies on these interactions. 12 Alternatively, Bax/Bak activation may be facilitated by other means, for example, the remodeling of the outer mitochondrial membrane by Drp1. 32 It is, therefore, possible that the neutralization of active Bcl-xL by Noxa can somehow affect Drp1-mediated membrane remodeling.
Overall, this study used a loss-of-function analysis of the entire Bcl-2 family and a biochemical analysis to define components of the Bcl-2 network and their actions responsible for the mitochondrial pathway following multiple apoptotic stimuli. The approach used and the concept of relevant Bcl-2 network in a given cell should be widely applicable for the study of apoptotic signaling in different cell types in response to various stimuli.
Materials and Methods
Antibodies and reagents. Antibodies used were as follows: Bmf antibody (Alexis Biochemicals, Lausen, Switzerland, ALX-804-343); Anti-Puma (Sigma, St. Louis, MO, USA, P4743); anti-Bik (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, SC-1710); anti-Bcl-xL (Cell Signaling Technology, Inc., Danvers, MA, USA, 2762 and 2764), anti-Bcl-xL (Sigma, B9429), anti-Mcl-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, S19), anti-Bcl-2 (Santa Cruz Biotechnology, Inc., Sc-509), anti-Bcl-w (Stressgen Biotechnologies, Inc., San Diego, CA, USA, AAP-050), anti-Bax (Santa Cruz Biotechnology, Inc., Sc-493,), anti-Bak (Upstate, Lake Placid, NY, USA. 04-433), Bak Ab-1 (Calbiochem, San Diego, CA, USA, AM03T), anti-Bad (Cell Signaling Technology, Inc., 9292), antiBim (Millipore, Billerica, MA, USA), anti-Noxa (Imgenex, San Diego, CA, USA, IMG-349A), anti-Bnip3 (Sigma, B7931), anti-Bid, 16 anti-FLAG (Sigma, F7415), b-Actin (Sigma, A5441). TG was purchased from Santa Cruz Biotechnology, Inc. MG-132 was purchased from Sigma. Human recombinant TRAIL was generated as previously described. 
